Prospects of replication-deficient adenovirus based vaccine development against SARS-CoV-2

Mariangela Garofalo , Monika Staniszewska , Stefano Salmaso , Paolo Caliceti , Katarzyna Wanda Pancer , Magdalena Wieczorek , Lukasz Kuryk

Abstract

The current appearance of the new SARS coronavirus 2 (SARS-CoV-2) and it quickly spreading across the world poses a global health emergency. The serious outbreak position is affecting people worldwide and requires rapid measures to be taken by healthcare systems and governments. Vaccinations represent the most effective strategy to prevent the epidemic of the virus and to further reduce morbidity and mortality with long-lasting effects. Nevertheless, currently there are no licensed vaccines for the novel coronaviruses. Researchers and clinicians from all over the world are advancing the development of a vaccine against novel human SARS-CoV-2 using various approaches. Herein, we aim to present and discuss the progress and prospects in the field of vaccine research towards SARS-CoV-2 using adenovirus (AdV) replication deficient-based strategies, with a comprehension that may support research and combat this recent world health emergency.

Author Mariangela Garofalo - [Università degli Studi di Padova]
Mariangela Garofalo,,
-
-
, Monika Staniszewska (FC / CDSB)
Monika Staniszewska,,
- Chair of Drug and Cosmetics Biotechnology
, Stefano Salmaso - [Università degli Studi di Padova]
Stefano Salmaso,,
-
-
, Paolo Caliceti - [Università degli Studi di Padova]
Paolo Caliceti,,
-
-
, Katarzyna Wanda Pancer - [National Institute of Public Health - National Institute of Hygiene (NIPH - NIH)]
Katarzyna Wanda Pancer,,
-
-
, Magdalena Wieczorek - [National Institute of Public Health - National Institute of Hygiene (NIPH - NIH)]
Magdalena Wieczorek,,
-
-
, Lukasz Kuryk - [National Institute of Public Health - National Institute of Hygiene (NIPH - NIH)]
Lukasz Kuryk,,
-
-
Journal seriesVaccines, ISSN 2076-393X
Issue year2020
Vol8
Pages1-10
Publication size in sheets0.5
Keywords in EnglishSARS-CoV-2; vaccine; adjuvant; adenovirus; COVID-19
ASJC Classification2725 Infectious Diseases; 2736 Pharmacology (medical); 2403 Immunology; 3002 Drug Discovery; 3004 Pharmacology
DOIDOI:10.3390/vaccines8020293
URL https://www.mdpi.com/2076-393X/8/2/293
Languageen angielski
File
wdpb_publikacje_pliki_plik_publikacja_3974_org.pdf 531.99 KB
Score (nominal)140
Score sourcejournalList
ScoreMinisterial score = 140.0, 01-07-2020, ArticleFromJournal
Publication indicators Scopus Citations = 0; Scopus SNIP (Source Normalised Impact per Paper): 2016 = 0.106; WoS Impact Factor: 2018 = 4.76 (2)
Citation count*
Cite
Share Share

Get link to the record


* presented citation count is obtained through Internet information analysis and it is close to the number calculated by the Publish or Perish system.
Back
Confirmation
Are you sure?